COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1

1 . A compound selected from:

or a pharmaceutically acceptable salt thereof;

wherein:

Degron is selected from:

D1 is selected from:

TL1 is a moiety that binds to BRD9 selected from

TL2 is a moiety that binds to BRD9 selected from

L 1 is selected from:

X 1 , X 2 , X 3 , and X 4 are independently selected from CR 4 and N, wherein no more than two of X 1 , X 2 , X 3 , and X 4 may be selected to be N;

X 5 and X 6 are independently selected from CR 4 and N;

Z 2 and Z 3 are selected from —CH 2 — and —C(O)— wherein at least one of Z 2 and Z 3 is —C(O)—;

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

o is 1, 2, 3, or 4;

each Q is independently 0, S, or NR 5 ;

R 1 is hydrogen or C 1 -C 6 alkyl;

R 2 , R 3 , and R 6 are independently selected from hydrogen and C 1 -C 6 alkyl;

each R 4 is independently selected from hydrogen, halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkyl;

each R 5 is independently hydrogen, C 1 -C 6 alkyl, or —C(O)alkyl;

R 7 is selected from halogen, hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkyl;

each R 8 is independently selected from hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl; or two R 8 groups together with the carbon to which they are attached form a cyclopropyl group;

L 2 is selected from: bond

L 3 is selected from bond, aryl, heterocycle, heteroaryl,

m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

R 10 is selected from C 1 -C 6 alkyl, cycloalkyl, heterocycle, heteroaryl, —C 1 -C 6 alkyl-aryl, and aryl; each of which R 10 group is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11 ;

R 11 is selected from hydrogen, halogen, —NR 1 R 14 , —OR 11 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —SO 2 NR 1 R 14 , —SO 2 OR 14 , —SONR 1 R 14 , and —S(O)OR 14 ;

each R 12 is independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkyl;

R 13 is selected from hydrogen, C 1 -C 6 alkyl, cycloalkyl, and heterocycle; each of which cycloalkyl and heterocycle is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11 ; and

each instance of R 14 is independently selected from hydrogen, C 1 -C 6 alkyl, C(O)alkyl, and C(O)NR 1 R 1 .

2 . The compound of claim 1 , wherein TL1 is:

3 . The compound of claim 1 , wherein TL1 is:

4 . The compound of claim 1 , wherein the compound is selected from

or a pharmaceutically acceptable salt thereof;

wherein

Z is CH 2 or C(O).

5 . The compound of claim 1 , wherein the compound is selected from

or a pharmaceutically acceptable salt thereof;

wherein

Z is CH 2 or C(O).

6 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof;

wherein

Z is CH 2 or C(O).

8 . The compound of claim 1 , wherein L 2 -L 3 is selected from:

9 . The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof;

wherein

Z is CH 2 or C(O).

10 . The compound of claim 1 , wherein Z 2 and Z are C(O).

11 . The compound of claim 1 , wherein R 1 is hydrogen.

12 . The compound of claim 1 , wherein R 5 is hydrogen.

13 . The compound of claim 1 , wherein R 5 is C 1 -C 6 alkyl.

14 . The compound of claim 1 , wherein n is 0, 1, 2, or 3.

15 . The compound of claim 1 , wherein Degron or D1 are selected from:

or a pharmaceutically acceptable salt thereof.

16 . The compound of claim 1 , wherein the compound is selected from Table 1 or a pharmaceutically acceptable salt thereof.

17 . The compound of claim 1 , wherein the compound is selected from Table 2 or a pharmaceutically acceptable salt thereof.

18 . A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19 . A method for treating a BRD9 or MTH1 mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

20 . The method of claim 19 , wherein the subject is a human.